Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VCT220 in Overweight or Obese Participants
NCT06939296Phase 3Completed
- Sponsor
- Vincentage Pharma Co., Ltd.
- Start
- Dec 2024
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of VCT220 in obesity, sponsored by Vincentage Pharma Co., Ltd.. Started Dec 2024; status: completed.
02
Drugs
VCT220
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06939296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06939296.